ARVINAS INC. - COMMON STOCK

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

30 Jul 2025 13:05:54 By Nasdaq GlobeNewswire

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

09 Jul 2025 04:00:00 By Nasdaq GlobeNewswire

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

13 Jun 2025 04:00:28 By Nasdaq GlobeNewswire

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

06 Jun 2025 04:00:03 By Nasdaq GlobeNewswire

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

05 Jun 2025 05:28:29 By Nasdaq GlobeNewswire

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

31 May 2025 05:00:50 By Nasdaq GlobeNewswire

Arvinas to Present at Jefferies Global Healthcare Conference

30 May 2025 04:00:00 By Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

01 May 2025 04:00:24 By Nasdaq GlobeNewswire

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

28 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

28 Apr 2025 03:45:37 By Nasdaq GlobeNewswire

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 Apr 2025 07:44:25 By Nasdaq GlobeNewswire

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

21 Apr 2025 04:00:54 By Nasdaq GlobeNewswire

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

04 Apr 2025 04:00:08 By Nasdaq GlobeNewswire

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

27 Mar 2025 04:00:24 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

11 Mar 2025 03:45:00 By Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 Mar 2025 13:05:09 By Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

11 Feb 2025 04:00:04 By Nasdaq GlobeNewswire

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

03 Feb 2025 04:00:49 By Nasdaq GlobeNewswire

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

10 Jan 2025 04:00:19 By Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

10 Dec 2024 06:05:00 By Nasdaq GlobeNewswire